A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding ’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information. Is the behavior connected to dementia, or was it ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Read about a study finding a single, low-dose of methylene blue in healthy people boosted their short-term memory by activating relevant brain regions.

Foralumab helped to normalize microglial cell activity - tied to Alzheimer's progression - in the mice, leading to signs of better cognition.

Columnist Ray Burow clarifies some common misconceptions about Alzheimer's disease, particularly that it's a type of mental illness.

Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.